Andrew Feilden

Andrew Feilden has a diverse work experience in the field of analytical sciences and chemistry operations. Andrew currently serves as the Director of Analytical Sciences at Bicycle Therapeutics since October 2022. Before that, they worked as the E&L European Strategic Director at Hall Analytical from November 2019 to October 2022. Prior to that, they held the role of Technical Director at Smithers Rapra from September 2018 to November 2019.

From October 2012 to November 2019, Andrew worked at Smithers Rapra Ltd. in two different roles. First, they were the Chemistry Operations Director, responsible for overseeing chemistry operations. Later, they transitioned into the role of Principal Consultant, providing expert consultancy in the field of chemistry.

Andrew's career began at AstraZeneca in November 1998, where they worked as a Senior Scientist until June 2011. Andrew continued in the same role but with an unknown start date until the end of June 2011.

Andrew Feilden attended the University of York from 1990 to 1997, where they obtained a BSc and D.Phil degree in Chemistry. In March 2021, they obtained the certification of Fellow Chartered Chemist from the Royal Society of Chemistry.